UBS Group AG shares fall 1.26% premarket after UBS analyst downgrades DOCMORRIS rating and target price.

UBS Group AG fell 1.26% in premarket trading. The decline aligns with UBS's analyst Sebastian Vogel maintaining a Sell rating on DOCMORRIS, with a revised target price of CHF 5.90, down from CHF 8.00. Additionally, UBS's neutral rating on L'Oréal, citing poor signals from US peers and a 13% downside potential, may have contributed to the negative sentiment.